Sign In
Buy NBY
$1.47
+0 (+0%)
At Close: Jun 08, 2026
NovaBay Rebrands To Stablecoin Development Corp In Full Crypto Pivot— Pharma Company's Stock Climbs 19%
12:00am, Tuesday, 24'th Mar 2026
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) announced Monday its corporate name change to Stablecoin Development Corporation, signaling a full shift toward a cryptocurrency-focused strategy.
Following $134 million investment from R01 Fund LP, Framework Ventures, Tether Investments, S.A. de C.V., and Sky Frontier Foundation, Stablecoin Development Corporation has acquired 2.06 billion SK
Why Did KALA BIO Shares Jump Over 22% After Hours?
12:20am, Thursday, 04'th Dec 2025
KALA BIO shares jumped over 22% after Oxford Finance acquired a 16.5% stake, amid recent leadership changes and continued year-to-date losses.
What Sparked KALA BIO's Nearly 38% Surge Overnight?
12:34am, Wednesday, 26'th Nov 2025
KALA BIO shares surged over 37% in after-hours trading following a private placement, loan settlement, and leadership changes.
NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards
07:07pm, Monday, 20'th Oct 2025
EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's
EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) previously announced a one-time special cash dividend of $0.80 per share
NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
05:25pm, Tuesday, 19'th Aug 2025
Investment to support NovaBay's continued public listing and provide funding for a future strategic transaction Investment to support NovaBay's continued public listing and provide funding for a futur
NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders
06:50am, Friday, 07'th Mar 2025
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces it will hold a virtual Special Meeting on April 16, 2025, at wh
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why
01:01pm, Wednesday, 25'th Dec 2024
NovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
06:50am, Thursday, 19'th Dec 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that its Reconvened Special Meeting of Stockholders held on Dec
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting
06:50am, Monday, 09'th Dec 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that Chief Executive Officer Justin Hall has issued the followi
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
04:05pm, Friday, 22'nd Nov 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that its Special Meeting of Stockholders held on November 22, 2
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the largest institutional advisory firm, Institutional Sha
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NovaBay Pharmaceuticals, Inc.'s (NYSE American: NBY) Avenova brand and business to Physic
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals
08:30am, Friday, 20'th Sep 2024
This Acquisition Enhances PRN Physician Recommended Nutriceuticals' ("PRN") Product Portfolio of Science-Based Eye Health Products BLUE BELL, Pa. , Sept. 20, 2024 /PRNewswire/ -- Acumen Health Holdin
